TeLoRmedix SA, (Lugano, Switzerland) is a Swiss-based biopharmaceutical company formed to develop immunoselective cancer drugs targeting Toll-like Receptors (TLRs) with an initial focus on superficial bladder cancer. TLRs are receptors that modulate the innate immune response. The company focuses on drugs that have been previously tested in humans, have favorable safety profile and an innovative scientific rationale. This approach allows to rapidly developing drugs designed to be very selective and well tolerated. Telormedix will also exclusively license a library of new TLR molecules from the University California San Diego (UCSD) that have already shown efficacy in pre-clinical animal models of various diseases.